Tests inobrodib with pomalidomide and dexamethasone in relapsed myeloma
Tests inobrodib with two other drugs in adults with returned multiple myeloma.
Plain-language title generated from the registry record
Registry title: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Bebington, Cardiff, Edinburgh, London, Oxford, Southampton, Sutton, and Withington, United KingdomSee the 10 sites
- Phase
- Phase 2
Where in United Kingdom
- The Clatterbridge Cancer Centre NHS Foundation TrustBebington, United KingdomTaking people
- University Hospital of WalesCardiff, United KingdomTaking people
- Western General HospitalEdinburgh, United KingdomTaking people
- Barts Health NHS TrustLondon, United KingdomTaking people
- Imperial College Healthcare Nhs Trust - Hammersmith HospitalLondon, United KingdomTaking people
- King's College Hospital NHS Foundation TrustLondon, United KingdomTaking people
- Oxford University Hospitals NHS Foundation TrustOxford, United KingdomTaking people
- University Hospital Southampton NHS Trust, Southampton General HospitalSouthampton, United KingdomTaking people
- Royal Marsden NHS Foundation TrustSutton, United KingdomTaking people
- The Christie NHS Foundation TrustWithington, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CellCentric Ltd.
- Trial code
- NCT07096778
- Record updated
- 21 September 2026
- Original description
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.Read full original descriptionShow less
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Inclusion: Male or female ≥18 years of age; Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy; Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2; Adequate hematological, renal and hepatic function; Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners.
Exclusion: Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; Prior treatment with p300/CBP bromodomain inhibitors; Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide); Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment; Major surgery within 4 weeks of the first dose of study treatment; Live vaccine within 4 weeks of study treatment; Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma; Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data; Active or unresolved adverse events; Female patients who are pregnant or breast-feeding at any time during the study.